Jiang P, Jing S, Sheng G, Jia F
Front Immunol. 2024; 15:1420205.
PMID: 39221244
PMC: 11361984.
DOI: 10.3389/fimmu.2024.1420205.
Moraes Ribeiro E, Secker K, Nitulescu A, Schairer R, Keppeler H, Wesle A
J Immunother Cancer. 2024; 12(1).
PMID: 38296597
PMC: 10831439.
DOI: 10.1136/jitc-2023-007829.
Zhao W, Li M, Song S, Zhi Y, Huan C, Lv G
Front Cell Dev Biol. 2024; 11:1274361.
PMID: 38250325
PMC: 10796773.
DOI: 10.3389/fcell.2023.1274361.
Rashu R, Ninkov M, Wardell C, Benoit J, Wang N, Meilleur C
PLoS Pathog. 2023; 19(6):e1011485.
PMID: 37384813
PMC: 10337970.
DOI: 10.1371/journal.ppat.1011485.
Balasko A, Kowatsch M, Graydon C, Lajoie J, Fowke K
Sci Rep. 2023; 13(1):10082.
PMID: 37344517
PMC: 10284876.
DOI: 10.1038/s41598-023-36468-8.
Programmed death ligand 1 regulates epithelial-mesenchymal transition and cancer stem cell phenotypes in hepatocellular carcinoma through the serum and glucocorticoid kinase 2/β-catenin signaling pathway.
Kong X, Peng H, Liu P, Fu X, Wang N, Zhang D
Cancer Sci. 2023; 114(6):2265-2276.
PMID: 36751987
PMC: 10236605.
DOI: 10.1111/cas.15753.
Targeting immune checkpoints: how to use natural killer cells for fighting against solid tumors.
Ghaedrahmati F, Esmaeil N, Abbaspour M
Cancer Commun (Lond). 2022; 43(2):177-213.
PMID: 36585761
PMC: 9926962.
DOI: 10.1002/cac2.12394.
Identification of a PD-L1+Tim-1+ iNKT subset that protects against fine particulate matter-induced airway inflammation.
Thio C, Lai A, Wang J, Chi P, Chang Y, Ting Y
JCI Insight. 2022; 7(23).
PMID: 36477357
PMC: 9746902.
DOI: 10.1172/jci.insight.164157.
PD-1 expression, among other immune checkpoints, on tumor-infiltrating NK and NKT cells is associated with longer disease-free survival in treatment-naïve CRC patients.
Al-Mterin M, Murshed K, Elkord E
Cancer Immunol Immunother. 2022; 72(6):1933-1939.
PMID: 36436018
PMC: 10198836.
DOI: 10.1007/s00262-022-03337-8.
In the Acute Phase of Infection, Liver Lymphoid and Myeloid Cells Display an Ambiguous Phenotype Combining Pro- and Anti-Inflammatory Markers.
Dos Santos C, Vacani-Martins N, Cascabulho C, Pereira M, Crispe I, Henriques-Pons A
Front Immunol. 2022; 13:868574.
PMID: 35720410
PMC: 9204308.
DOI: 10.3389/fimmu.2022.868574.
Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy.
Long Y, Yu X, Chen R, Tong Y, Gong L
Front Immunol. 2022; 13:910704.
PMID: 35663968
PMC: 9157498.
DOI: 10.3389/fimmu.2022.910704.
Regulation of the innate immune cells during pregnancy: An immune checkpoint perspective.
Li W, Xu X, Jin L
J Cell Mol Med. 2021; 25(22):10362-10375.
PMID: 34708495
PMC: 8581333.
DOI: 10.1111/jcmm.17022.
Inhibiting the Unconventionals: Importance of Immune Checkpoint Receptors in γδ T, MAIT, and NKT Cells.
Catafal-Tardos E, Baglioni M, Bekiaris V
Cancers (Basel). 2021; 13(18).
PMID: 34572874
PMC: 8467786.
DOI: 10.3390/cancers13184647.
Soluble B7-CD28 Family Inhibitory Immune Checkpoint Proteins and Anti-Cancer Immunotherapy.
Khan M, Arooj S, Wang H
Front Immunol. 2021; 12:651634.
PMID: 34531847
PMC: 8438243.
DOI: 10.3389/fimmu.2021.651634.
Natural killer T cell immunotherapy combined with oncolytic vesicular stomatitis virus or reovirus treatments differentially increases survival in mouse models of ovarian and breast cancer metastasis.
Gebremeskel S, Nelson A, Walker B, Oliphant T, Lobert L, Mahoney D
J Immunother Cancer. 2021; 9(3).
PMID: 33722907
PMC: 7970295.
DOI: 10.1136/jitc-2020-002096.
Targeting cancer stem cells for reversing therapy resistance: mechanism, signaling, and prospective agents.
Zhou H, Zhang J, Zhang X, Li Q
Signal Transduct Target Ther. 2021; 6(1):62.
PMID: 33589595
PMC: 7884707.
DOI: 10.1038/s41392-020-00430-1.
Type I Natural Killer T Cells as Key Regulators of the Immune Response to Infectious Diseases.
Galvez N, Bohmwald K, Pacheco G, Andrade C, Carreno L, Kalergis A
Clin Microbiol Rev. 2020; 34(2).
PMID: 33361143
PMC: 7950362.
DOI: 10.1128/CMR.00232-20.
Natural Killer T-Cell Agonist α-Galactosylceramide and PD-1 Blockade Synergize to Reduce Tumor Development in a Preclinical Model of Colon Cancer.
Wang Y, Bhave M, Yagita H, Cardell S
Front Immunol. 2020; 11:581301.
PMID: 33193386
PMC: 7606378.
DOI: 10.3389/fimmu.2020.581301.
The Crossroads between Infection and Bone Loss.
Carvalho Oliveira T, Gomes M, Gomes A
Microorganisms. 2020; 8(11).
PMID: 33182721
PMC: 7698271.
DOI: 10.3390/microorganisms8111765.
Harnessing Unconventional T Cells for Immunotherapy of Tuberculosis.
La Manna M, Orlando V, Tamburini B, Badami G, Dieli F, Caccamo N
Front Immunol. 2020; 11:2107.
PMID: 33013888
PMC: 7497315.
DOI: 10.3389/fimmu.2020.02107.